# BPC-157 FAQ: Safety, Dosing, Access, and the Honest Limits > BPC-157 questions answered against the published record: side effects, organ safety, the cancer question, oral use, half-life, legal status and 503A, BPC-157 vs TB-500, and what the human evidence does and does not show. Each answer leads with the finding and cites the study. Where the record is thin — and for BPC-157 it often is — the answer says so. ## Does BPC-157 damage the liver? Animal hepatoprotection models report reduced, not increased, liver lesions, and a small human IV pilot saw no measurable changes in hepatic biomarkers in two adults [5][9]. The literature frames BPC-157 as hepatoprotective. Long-term human liver-safety data are absent, so the reassurance is bounded by sample size, not confirmed by it. ## Is BPC-157 hard on the kidneys? The 2-person IV safety pilot reported no measurable renal biomarker changes [5], and rodent distant-organ models describe kidney protection rather than injury [9]. Human evidence is minimal. The signal points toward protection, but the human data are far too sparse to characterize renal risk. ## Can BPC-157 mess with your heart? The IV pilot found no measurable cardiac biomarker changes in two adults [5], and rodent cardiac models describe protective effects. There are no controlled human cardiovascular safety data. Two people tolerating an infusion is encouraging and is not a cardiovascular safety trial. ## Is BPC-157 bad for the heart? No human study has shown cardiac harm, but the human dataset is two people [5]. Cardiovascular safety in humans is genuinely unknown. The question has barely been posed at human scale, which is different from having been answered. ## Can BPC-157 cause liver damage? Published animal work and one tiny human pilot do not show liver damage; the record frames BPC-157 as hepatoprotective, with rat studies showing protection from distant-organ injury and the IV pilot showing no hepatic biomarker changes [5][9]. This is not a substitute for long-term human safety data, which do not exist. ## How long should I stay on BPC-157? No validated human duration exists. Published doses are per-kilogram animal-model figures, not human protocols, and there is no clinical guidance on length of use [1][8]. The literature contains no human duration to cite. ## What happens when you stop taking BPC-157? The literature does not characterize discontinuation effects in humans. With a sub-30-minute half-life in animal pharmacokinetics, the parent peptide clears quickly [2], but no human withdrawal or discontinuation data exist. Rapid clearance is an animal finding, not a description of a human experience. ## What should you not mix with BPC-157? No human drug-interaction studies exist. Rodent work actually pairs BPC 157 with NSAIDs to study counteraction of diclofenac toxicity [1], which is an experimental model and not interaction guidance for people. The honest answer is that human interaction data are simply unavailable. ## Can you drink alcohol while taking BPC-157? There is no human data on alcohol co-use. Rodent studies examine BPC 157 against alcohol-induced gastric and liver lesions [1][4], which is a protection model, not a translation to human safety advice. Nothing in the record speaks to combining the two in a person. ## Does BPC-157 cause cancer? No study reports BPC-157 causing cancer. Because its proposed mechanism is pro-angiogenic [3], long-term oncologic safety in humans has not been established, and the three small pilots carry no long-term follow-up [8]. Absence of reported harm at this sample size is not evidence of long-term safety. ## Does BPC-157 have side effects? Within the tiny human dataset — two IV-pilot adults, a 12-patient intravesical pilot, and a small intra-articular case series — no adverse events were reported [5][6][7]. The absence of large, long-term trials means the side-effect profile is not fully known. A small clean record is a small record. ## How long can you take BPC-157? No validated human duration exists. All formal dosing is expressed per kilogram in animals, and there is no clinical recommendation for length of human use [1][8]. Specific durations seen online are extrapolations, not findings. ## What does BPC-157 do in the body? In animal models BPC-157 is described as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis via VEGFR2-Akt-eNOS signaling [3]. It has accelerated tendon and gastric-ulcer healing and protected distant organs in rodents [1][4][9]. Its effect in the human body has been examined in only three small pilots, none of them efficacy trials [5][6][7]. ## Is BPC-157 a growth hormone? No. BPC-157 is a 15-amino-acid peptide, not a growth hormone [2]. One tendon-fibroblast study does report that it up-regulates the growth-hormone receptor at mRNA and protein levels [1], but up-regulating a receptor is not the same as being a hormone. ## Can BPC-157 be taken orally? It is called a "stable gastric pentadecapeptide" because it is reported stable in gastric juice, and it was studied intragastrically in animals [2][4]. Formal human oral pharmacokinetics, however, are not established. Stability in the stomach is the precondition for oral interest, not proof of oral efficacy in people. ## Does oral BPC-157 work? In the rat gastric-ulcer work, intramuscular delivery outperformed intragastric [4], and human oral pharmacokinetics are not established [2], so oral efficacy in people is unproven. The peptide's gastric stability keeps the oral question open; the comparative animal data and the absent human PK keep it unanswered. ## Does BPC-157 work immediately? The literature describes effects over days of repeated dosing in animal healing models, not an immediate result [1][4]. No human onset timeline is established. The repair findings are measured across a healing course, which is the opposite of an instant effect. ## How does BPC-157 make you feel? There is no human subjective-effect data. Rodent CNS studies report behavioral and serotonergic/dopaminergic changes [1], but animal neurochemistry does not describe a human experience. The record contains no account of how BPC-157 "feels" in a person. ## How long does BPC-157 take to work? Animal healing studies report improvement over repeated daily dosing rather than a defined onset [1][4]. No validated human timeline exists. The timing evidence is entirely from animal repair models, not human use. ## How long does it take for BPC-157 to kick in? No human onset data exist. The honest answer is that all timing evidence comes from animal repair models with repeated dosing over days [1][4], not from human use, so there is no human "kick-in" figure to give. ## Can BPC-157 help with weight loss? No. Weight-loss claims are not supported by the published evidence and should be treated skeptically. The BPC-157 literature is a tissue-repair and cytoprotection literature [1][4][8]; it does not contain weight-loss findings. ## Does BPC-157 build muscle? Animal models show recovery from muscle crush injury, not muscle-building in healthy subjects, so muscle-growth claims are not supported by the evidence [1][8]. Repairing damaged muscle and adding muscle to a healthy body are different claims, and only the first appears in the record. ## How to Read BPC-157 'Reviews' Against the Evidence Treat BPC-157 reviews and testimonials as anecdote, not data. The published record is what this site cites: a large preclinical literature, a coherent angiogenesis mechanism [3], and three small human pilots [5][6][7]. A 2025 narrative review calls the compound investigational and urges caution given limited human data and non-regulated availability [8] — a more reliable summary than any user report. ## BPC-157 vs TB-500 BPC-157 and TB-500 are different peptides with different mechanisms: BPC-157 is a 15-amino-acid gastric pentadecapeptide studied for cytoprotection and VEGFR2-driven angiogenesis [2][3], while TB-500 is a fragment of thymosin beta-4. This site covers BPC-157 only and makes no comparative-efficacy claim. Notably, both BPC-157 and TB-500 sit in FDA's 503A Category 2 and both appear on the July 2026 PCAC agenda as substances under evaluation [11][12]. ## Is BPC-157 legal? BPC-157 is not an FDA-approved drug and was placed by FDA in 503A Category 2 (effective September 29, 2023), meaning it is not within FDA's enforcement-discretion policy for 503A compounding [12]. It is also WADA-prohibited in sport. See the [BPC-157 legal status](/legal-status) page for the full, FDA-cited picture, including the scheduled July 2026 PCAC discussion. ## Can you get BPC-157 from a compounding pharmacy? As of today, BPC-157's Category 2 status means it is not eligible for routine 503A compounding while that status stands [12][13]. A legally compounded preparation requires an eligible ingredient plus a licensed-prescriber evaluation and a valid patient-specific prescription. The [BPC-157 legal status](/legal-status) page describes the lawful pathway in general terms and the July 2026 PCAC evaluation. ## What is the FDA 503A status of BPC-157? FDA placed BPC-157 ("BPC-157 (free base)" and "BPC-157 acetate") in 503A Category 2 — bulk substances it identified as potentially presenting significant safety risks — effective with its September 29, 2023 update, so it is not afforded enforcement discretion for 503A compounding [12]. BPC-157 is separately named on the July 2026 PCAC agenda as a substance under consideration for the 503A bulks list [11]. See the [FDA 503A compounding category](/legal-status) page for detail. --- A stained-glass reading of the BPC-157 record — each finding set in its own pane, cited to the source, with no clinic behind the glass and nothing here for sale.